Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of BI 730357 (Bevurogant) in Healthy Male Volunteers
NCT03664011Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Primary endpoints: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-tz) and Mass Balance Recovery of Total [14C]-Radioactivity in Faeces (Fefaeces, 0-tz). Started Sep 2018; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03664011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664011.